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Summary
Background The effectiveness of the COVID-19 vaccination programme depends on mass participation: the greater 
the number of people vaccinated, the less risk to the population. Concise, persuasive messaging is crucial, particularly 
given substantial levels of vaccine hesitancy in the UK. Our aim was to test which types of written information about 
COVID-19 vaccination, in addition to a statement of efficacy and safety, might increase vaccine acceptance.
Methods For this single-blind, parallel-group, randomised controlled trial, we aimed to recruit 15 000 adults in the UK, 
who were quota sampled to be representative. Participants were randomly assigned equally across ten information 
conditions stratified by level of vaccine acceptance (willing, doubtful, or strongly hesitant). The control information 
condition comprised the safety and effectiveness statement taken from the UK National Health Service website; the 
remaining conditions addressed collective benefit, personal benefit, seriousness of the pandemic, and safety concerns. 
After online provision of vaccination information, participants completed the Oxford COVID-19 Vaccine Hesitancy 
Scale (outcome measure; score range 7–35) and the Oxford Vaccine Confidence and Complacency Scale (mediation 
measure). The primary outcome was willingness to be vaccinated. Participants were analysed in the groups they were 
allocated. p values were adjusted for multiple comparisons. The study was registered with ISRCTN, ISRCTN37254291.
Findings From Jan 19 to Feb 5, 2021, 15 014 adults were recruited. Vaccine hesitancy had reduced from 26·9% the 
previous year to 16·9%, so recruitment was extended to Feb 18 to recruit 3841 additional vaccine-hesitant adults. 
12 463 (66·1%) participants were classified as willing, 2932 (15·6%) as doubtful, and 3460 (18·4%) as strongly hesitant 
(ie, report that they will avoid being vaccinated for as long as possible or will never get vaccinated). Information 
conditions did not alter COVID-19 vaccine hesitancy in those willing or doubtful (adjusted p values >0·70). In those 
strongly hesitant, COVID-19 vaccine hesitancy was reduced, in comparison to the control condition, by personal 
benefit information (mean difference –1·49, 95% CI –2·16 to –0·82; adjusted p=0·0015), directly addressing safety 
concerns about speed of development (–0·91, –1·58 to –0·23; adjusted p=0·0261), and a combination of all 
information (–0·86, –1·53 to –0·18; adjusted p=0·0313). In those strongly hesitant, provision of personal benefit 
information reduced hesitancy to a greater extent than provision of information on the collective benefit of not 
personally getting ill (–0·97, 95% CI –1·64 to –0·30; adjusted p=0·0165) or the collective benefit of not transmitting 
the virus (–1·01, –1·68 to –0·35; adjusted p=0·0150). Ethnicity and gender were found to moderate information 
condition outcomes.
Interpretation In the approximately 10% of the population who are strongly hesitant about COVID-19 vaccines, 
provision of information on personal benefit reduces hesitancy to a greater extent than information on collective 
benefits. Where perception of risk from vaccines is most salient, decision making becomes centred on the personal. 
As such, messaging that stresses the counterbalancing personal benefits is likely to prove most effective. The 
messaging from this study could be used in public health communications. Going forwards, the study highlights 
the need for future health campaigns to engage with the public on the terrain that is most salient to them.
Funding National Institute for Health Research (NIHR) Oxford Biomedical Research Centre and NIHR Oxford Health 
Biomedical Research Centre.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
In October, 2020, we did a survey of UK adults to estimate 
how many people would agree to be vaccinated for 
COVID-19, to discover whether there were parts of the 
population who were especially reluctant and, most 
importantly, to determine why people might not agree to 
take an approved vaccine.1 Our aim was to inform the 
provision of accurate vaccination information that will 
increase acceptance rates. 5114 adults, representative of 
the UK population for age, gender, ethnicity, income, and 
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region, took part in the Oxford Coronavirus Explanations, 
Attitudes, and Narratives Survey II (OCEANS-II). We 
found that 72% of the population were willing to be 
vaccinated, 17% were doubtful, and 12% were strongly 
hesitant. Although vaccine hesitancy was associated with 
younger age, female gender, lower income, and ethnicity, 
it was spread over the whole of the population, and not 
confined to particular sociodemo graphic groups. What 
mattered most were the beliefs people held about a 
COVID-19 vaccine—specifically, the potential collective 
benefit, the likelihood of COVID-19 infection, the effective-
ness of a vaccine, its side-effects, and the speed of vaccine 
development. Those who were hesitant about a COVID-19 
vaccine tended to be people who were less aware of the 
public health benefits of vaccination, did not consider 
themselves at high risk of illness, doubted the efficacy of a 
vaccine, worried about potential side-effects, or feared that 
it had been developed too quickly. The factor most strongly 
associated with vaccine acceptance was the awareness 
of collective benefit. We used these insights to develop 
OCEANS-III, a randomised controlled trial to test the 
effect of different types of written information on 
willingness to be vaccinated.
There have been four previous online randomised con-
trolled studies, conducted before the approval of COVID-19 
vaccines, that assessed aspects of information provision 
and vaccine acceptance. Informing people that a COVID-19 
vaccine is safe and effective increases acceptance compared 
Research in context
Evidence before this study
Following PRISMA guidelines, we searched MEDLINE, Embase, 
PsychInfo, and medRxiv from Jan 1, 2020, to Feb 24, 2021, using 
the search terms (COVID-19 OR Coronavirus OR SARS-CoV-2) 
AND (vaccine OR vaccination OR immunization) AND (hesitancy 
OR confidence OR uptake OR acceptance). We found 937 papers, 
of which four used a randomised controlled design to examine 
the effect of information provision on COVID-19 vaccine 
hesitancy. A US study done in August, 2020, with 
1123 respondents found that providing information that a 
vaccine is safe and effective, compared with no information, 
increased vaccine acceptance. In a French study done in 
July, 2020, with a representative group of 1942 people, there 
was no overall effect on vaccine acceptance from the provision 
of information on the benefit of herd immunity. Within the 
group, however, those individuals who outright refused 
vaccination (28·8%) were not affected by information on the 
benefit of herd immunity, but for those who did not refuse 
vaccination outright (71·2%), information on the benefit of herd 
immunity increased acceptance slightly. In a German study with 
1349 members of the general population done in 
November, 2020, vaccine acceptance was not influenced by 
information on the individual and prosocial benefits of herd 
immunity. In a study of 8000 people in the UK and the USA in 
September, 2020, provision of negative misinformation, 
compared with factual information, reduced acceptance.
Added value of this study
The overarching question addressed in our study was whether 
there is specific brief content about COVID-19 vaccination, 
above a statement of safety and effectiveness, that might 
reduce hesitancy or consolidate existing positive views in the 
general population. The study was done after the COVID-19 
vaccination programme had started in the UK. It was a large 
study, testing multiple different conditions of interest, and 
included outcome tests, moderation, and mediation. The study 
shows that for individuals who are initially strongly hesitant 
(ie, will avoid being vaccinated for as long as possible or will 
never get vaccinated), the most effective message for reducing 
hesitancy highlighted the personal benefits of vaccination 
(eg, that vaccination can prevent serious illness or long-term 
COVID-19-related problems). Addressing personal benefit was 
better than addressing collective benefit. It is also helpful in 
this subgroup to directly address safety concerns about the 
speed of development of the vaccines. Mediation of effects by 
changes in underlying views about COVID-19 vaccines was not 
found. The various information conditions tested, including 
those that reduced hesitancy in the strongly hesitant, did not 
change hesitancy levels either in people who were already 
willing to be vaccinated or those who were doubtful (ie, those 
who would delay vaccination or who did not know whether 
they would agree to receive the vaccine). There might be 
differences in impact of messages by gender and ethnicity, 
with participants of Black ethnicity sometimes reacting 
oppositely (more negatively) to the information provision 
conditions in comparison with the statement of safety 
and efficacy.
Implications of all the available evidence
The overwhelming majority in the UK are willing to be 
vaccinated for COVID-19 and can appreciate the collective 
benefits. In the small proportion, approximately 10% at the 
time of the study, who are strongly COVID-19 vaccine hesitant, 
and less inclined to see the collective benefit of vaccination, 
it is likely to be better to highlight personal rather than 
collective benefit in information provision. This group also 
show greater concerns about the speed of development of the 
vaccines and are responsive to information designed to address 
these fears. The information emphasis that reduces hesitancy in 
this subgroup does not affect vaccination attitudes in the rest 
of the population. None of the messaging lowered hesitancy in 
those who were doubtful about vaccination; research is needed 
to identify messaging that is especially effective for this group. 
Research also needs to consider the moderation of messages by 
gender and ethnicity. This study provides clear text for 
information provision in UK vaccine programmes. It was not 
determined how the successful information worked or whether 
the study findings can be generalised to other countries.
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with a no-information condition.2 Provision of information 
on the collective herd immunity benefit of vaccination has 
shown no overall population effect on vaccine acceptance.3,4 
However, in one study, those who refuse COVID-19 
vaccines outright were unaffected by a statement of the 
collective benefit of vaccina tion, whereas the provision of 
such information was associated with slightly higher 
acceptance in the rest of the population.4 Moderation of the 
effects of different messages is highly plausible, especially 
by level of vac cine hesitancy. Negative misinformation, 
compared with factual information, has been found to 
reduce vaccine acceptance.5
In OCEANS-III, we assumed that a basic statement of 
efficacy and safety—reproduced from the UK National 
Health Service (NHS) website—should occur in all 
information provision. We then tested the effects of 
additional short sections of text that addressed collective 
benefits of vaccination (arising from not getting ill or not 
infecting others), personal benefits of vaccination, the 
seriousness of the virus, and the speed of development 
and testing of the vaccines. We tested pieces of information 
suitable for use online or in a brief single sheet of 
information as part of a vaccination programme. We also 
tested the effects of combining some of these messages. 
All messaging was designed to be accurate and to reduce 
hesitancy; there was no testing of information that we 
thought might hinder vaccine uptake. The primary 
outcome was willingness to be vaccinated. We aimed to 
test moderation of the effectiveness of messaging by 
hesitancy level and a number of sociodemographic factors. 




This study was a single-blind, parallel-group, randomised 
controlled trial, with planned mediation and moderation 
tests. The intervention and data collection were carried out 
online. Participants completed an item for stratification 
by vaccine hesitancy level, provided sociodemographic 
informa tion, read the vaccine information in their ran-
domly allotted condition, and then completed measures of 
COVID-19 vaccine hesitancy and COVID-19 com placency 
and confidence beliefs. The study received ethical approval 
from the University of Oxford Central University Research 
Ethics Committee (reference R74001/RE001).
Participants
We aimed to recruit 15 000 UK adults (≥18 years of age), 
who were quota sampled to be nationally representative for 
age, gender, region, education level, and ethnicity. The 
quotas were based on UK Office for National Statistics 
population estimates. The participants were recruited by 
the market research company Lucid. Lucid’s platform 
serves as a centralised source for survey responses, work-
ing with more than 250 survey suppliers. Lucid operates a 
marketplace in which they advertise the survey to suppliers, 
who provide individual participants, with sampling by 
Lucid from this pool. The advantage of using multiple 
survey sources is substantially less reliance on any 
particular demographic or segment of the population. 
Respondents were sourced from a variety of places: 
advertise ments and promotions across digital networks, 
inter net search, word of mouth and membership referrals, 
social networks, online and mobile games, affili ate 
marketing, banner advertisements, offerwalls, TV and 
radio advertisements, and offline recruitment with mail 
campaigns. Invited respondents were not told the topic of 
the survey before they provided provisional agree ment to 
complete it. The description of the purpose of the study 
provided to participants, after they had given provisional 
agreement, was as follows: “There are now approved 
vaccines for COVID-19 that will be rolled out in the UK 
over the coming months. We want to learn about people’s 
views about vaccination for COVID-19. In particular, we 
want to find out how many people would or would not 
wish to be vaccinated and the reasons behind their 
decision.” On the front page of the study website, partici-
pants were provided with ethical committee-approved 
information describing the study and were asked to 
complete online tick-boxes to indicate informed consent.
Study recruitment initially took place from Jan 19 to 
Feb 5, 2021. Owing to a reduction in vaccine hesitancy 
compared with OCEANS-II, recruitment of vaccine-
hesitant individuals was extended to Feb 18, 2021. The UK 
vaccination programme started on Dec 8, 2020, for 
which a priority list was used (eg, older adults, clinically 
extremely vulnerable individuals, front-line health and 
social care staff). By Jan 19, 2021, when study recruitment 
began, 4 609 740 first-dose vaccinations had been given 
in the UK and 460 625 second doses.6 Nearly 10% of 
the UK adult population had received a vaccination.
Randomisation and masking
Participants were randomly assigned online equally to 
ten information conditions, stratified by three levels 
of vaccine hesitancy (willing, doubtful, or strongly 
hesitant). Randomisation was done using a computer-
generated sequence. Participants were required to read 
their assigned information condition and, therefore, could 
not be masked to the fact they were given information. 
They were, however, unaware that other conditions 
existed. Participants completed the self-report outcome 
measures online, with study data collected by Lucid; 
therefore, the research team can be considered as masked 
in relation to outcome assessments. The research team 
had no contact with research participants.
Procedures
After agreeing to take part, participants answered a single 
question to determine their level of vaccine hesitancy: “If 
the vaccine was available at my GP surgery I would: (1) get 
it as soon as possible, (2) get it when I have time, (3) delay 
getting it, (4) avoid getting it for as long as possible, 
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(5) never get it, (6) don’t know.” As in OCEANS-II, the level 
of vaccine hesitancy was defined as willing (answer 1 or 2), 
doubtful (answer 3 or 6), or strongly hesitant (answer 4 or 5). 
This question was found in OCEANS-II to have the 
highest load (0·95) on the COVID-19 vaccine hesitancy 
latent factor but for that precise reason was not included in 
the primary outcome measure.1 That is, the stratifying 
question was designed not to be repeated in the principal 
outcome variable.
Participants were then asked to read the text associated 
with their assigned information condition. Condition 1 was 
the control group, with the text comprising the safety and 
effectiveness statement taken from the NHS website 
(table 1).7 Three conditions addressed collective benefit only 
(conditions 2, 3, and 4), one condition addressed personal 
benefit only (condition 5), one condition combined 
collective and personal benefits (condition 9), one condition 
addressed the seriousness of the pandemic (condition 6), 
two conditions addressed safety concerns (con ditions 7 
and 8), and the final condition was a full combination 
addressing benefit, seriousness, and safety concerns 
(condition 10; table 1). The full text of each infor ma tion 
condition is included in the appendix (pp 54–59). The 
added text for each specific condition (conditions 2, 3, 5, 6, 
7, and 8) had a word count within 20% of the mean. We 
consulted individuals from the Oxford Vaccine Group’s 
Public and Patient Involvement group for feedback on the 
written text.
After reading the text associated with their assigned 
information condition, participants completed a measure 
of COVID-19 vaccine hesitancy (outcome measure) and 
a measure of COVID-19 complacency and confidence 
beliefs (mediation measure). The outcome measure was 
the seven-item Oxford COVID-19 Vaccine Hesitancy Scale,1 
in which item-specific response options,6 coded from 1 to 5, 
are used. A “don’t know” option is also provided, which is 
excluded from scoring. Scores can range between 7 and 35, 
with higher scores indicating higher COVID-19 vaccine 
hesitancy. The scale was developed in consultation with 
members of the general public, including representatives 
of ethnic minority groups. 14 items were initially developed 
and completed by the OCEANS-II representative sample 
of 5114 UK adults. Exploratory and confirmatory factor 
analysis (CFA) was conducted to derive the seven-item 
scale. The seven-item scale produced an excellent CFA 
model fit on the OCEANS-II sample (full-information 
maximum likelihood χ²(14, n=2548)=93·370, p<0·0001; 
root mean square error of approximation 0·047; standard-
ised root mean residual 0·01; comparative fit index 0·993; 
Tucker-Lewis index 0·989). Convergent validity was 
shown against the Vaccine Hesitancy Scale,8 Vaccination 
Knowledge Scale,9 and Vaccine Conspiracy Beliefs Scale.10 
The Cronbach’s α for the Oxford COVID-19 Vaccine 
Hesitancy Scale in the current study was 0·98 (n=16 445), 
indicating high internal consistency.
The mediation measure was the 14-item Oxford Vaccine 
Confidence and Complacency Scale,1 which has four 
subscale scores (collective importance, efficacy, side-effects, 
and speed of development). Item-specific response 
options,11 coded from 1 to 5, are used. A “don’t know” option 
is also provided, which is excluded from scoring. Scores 
range from 14 to 60, with higher scores indicating more 
negative attitudes towards COVID-19 vaccination. The 
Cronbach’s α in the current study was 0·88 (n=14 661) for 
collective importance, 0·85 (n=15 407) for speed of develop-
ment, 0·71 (n=14 105) for efficacy, and 0·78 (n=15 080) for 
side-effects. The Cronbach’s α for all the scale items 
was 0·94 (n=10 584), indicating high internal consistency.
Participants provided sociodemographic information 
including age, gender, ethnicity, region of residence, level 
of education, employment status, income, housing 
situation, marital status, religious beliefs, and political 
orientation. Participants completed all steps of the trial in 
the same session.
See Online for appendix
Description
Condition 1 (control) Safety and effectiveness statement taken from the NHS website: the text was “The coronavirus (COVID-19) vaccines are safe 
and effective, and give you the best protection against coronavirus. They have been approved by the independent Medicines 
and Healthcare products Regulatory Agency (MHRA)”.7 This control statement features at the end of all other conditions.
Condition 2 (collective benefit) Adding the collective vaccination benefit of not personally getting ill
Condition 3 (collective benefit) Adding the collective vaccination benefit of not transmitting the virus to others
Condition 4 (collective benefit) Adding the collective vaccination benefits of not getting ill and not transmitting the virus (ie, combining conditions 2 and 3)
Condition 5 (personal benefit) Adding the personal benefit of getting vaccinated
Condition 6 (seriousness) Adding the seriousness of the pandemic (and that it is much more serious than seasonal influenza)
Condition 7 (safety, direct) Directly addressing concerns about vaccine safety related to speed of development
Condition 8 (safety, indirect) Indirectly addressing concerns about vaccine safety related to speed of development
Condition 9 (collective and 
personal benefit)
Adding the collective and personal benefits together (ie, combining conditions 4 and 5)
Condition 10 (full combination) Adding the information on the collective and personal benefits, the seriousness of the virus, and the information that 
indirectly addresses concerns about the speed of development (ie, combining conditions 4, 5, 6, and 8)
The full text for each information condition is included in the appendix (pp 54–59). NHS=National Health Service.
Table 1: Information conditions
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Outcomes
Our primary outcome was willingness to be vaccinated, as 
measured by the Oxford COVID-19 Vaccine Hesitancy 
Scale. We considered two specific primary outcome 
questions: (1) whether adding information about the 
collective benefit of vaccination from not getting ill, 
the collective benefit of vaccination from not spreading 
the virus, the personal benefit of getting vaccinated, the 
seriousness of SARS-CoV-2, or why speed of develop ment 
is not a problem (directly and indirectly) lead to lower levels 
of COVID-19 vaccine hesitancy compared with a simple 
statement that vaccination is efficacious and safe; and 
(2) whether combining information about collective 
and personal benefits, or about collective and personal 
benefits, the seriousness of the virus, and indirectly why 
the speed of development is not a problem, lead to lower 
levels of COVID-19 vaccine hesitancy than a simple 
statement that vaccination is efficacious and safe.
As part of our primary analysis, we also investigated 
whether the effect of information provision on COVID-19 
vaccine hesitancy was moderated by the three levels of 
hesitancy groupings (ie, willing to be vaccinated, doubtful, 
strongly hesitant). We were most interested in the effects 
on those in the general population who were doubtful 
(approximately 17% in OCEANS-II) or strongly hesitant 
(approximately 12%) about a COVID-19 vaccination.
There were four specific secondary outcome questions: 
(1) whether emphasising collective benefit is better 
(ie, leads to lower hesitancy) than emphasising personal 
benefit; (2) whether it is better to address why speed of 
development is not a problem either directly or indirectly; 
(3) whether combining information about personal and 
collective benefits is better than emphasising either 
personal or collective benefits alone; and (4) whether 
combining information about collective and personal 
benefits with the seriousness of the virus and indirectly 
why the speed of development is not a problem is better 
than just combining information about collective and 
personal benefits.
As part of our secondary analysis, we also investigated 
whether the effect of information provision on COVID-19 
vaccine hesitancy was moderated by age, gender, ethnicity, 
income, region, or level of COVID-19 health risk.
Finally, we considered the following mediation question: 
if a significant relationship exists between randomised 
information conditions and vaccine hesitancy, can that 
relationship be explained by COVID-19 vaccine views?
Adverse events were considered unlikely to occur (since 
we provided information that was accurate and aimed 
to encourage vaccine uptake). On the study’s opening 
webpage, participants were informed that if they had a 
concern about any aspect of the study that they should 
contact the lead author or the Chair of the Medical Sciences 
Interdivisional Research Ethics Committee at the 
University of Oxford. Contact details for both individuals 
were provided.
Statistical analysis
This study was powered to detect a change in hesitancy 
level for each of the three stratifying levels of hesitancy 
Figure: Trial profile
IP=Internet Protocol. *Speeders defined as completion time of a third of the median length of interview, or below what is standard best practice.
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level (willing, doubtful, and strongly hesitant). From 
OCEANS-II, we estimated that 71·7% of the general 
population are willing to be vaccinated, with a mean score 
on the Oxford COVID-19 Hesitancy Scale of 10·8 (SD 3·5); 
16·6% are doubtful, with a mean score of 24·2 (5·8); and 
11·7% are strongly hesitant, with a mean score of 30·6 (3·5). 
A sample size of 96 would be able to detect a three-point 
change in the doubtful group, and a sample size of 254 a 
three-point change in the strongly hesitant group, at 
90% power and a type 1 error at 0·5% (two-sided). For the 
willing groups, a sample size of 822 would be able to 
detect a one-point change. This gives a total sample 
size of 1172 required for each condition. We intended 
to recruit 15 000 participants to enable adjustment for 
multiple comparisons in the analysis.
The primary outcome, the Oxford COVID-19 Vaccine 
Hesitancy score, was analysed using a linear regression 
model. The linear regression model included the Oxford 
COVID-19 Vaccine Hesitancy Scale score as the response 
variable with the randomised group (conditions 2, 3, 4, 5, 
6, 7, 8, 9, and 10 vs condition 1 [control]). An interaction 
between baseline vaccine hesitancy (willing, doubtful, 
or strongly hesitant) and condition was fitted in the 
regression model to determine the effect of conditions in 
each hesitancy category. Predefined subgroup analyses 
were done on the Oxford COVID-19 Vaccine Hesitancy 
Scale to ascertain if effectiveness of specific informa-
tion conditions varied by individual characteristics (age, 
gender, ethnicity, income, region, and level of COVID-19 
health risk). Subgroup analyses were conducted by inclu-
sion of an interaction term of baseline subgroup by 
randomised group in separate regression models. Each 
of the regression models included the interaction term, 
adjusting for age, gender, ethnicity, income, region, level 
of COVID-19 health risk, and vaccine hesitancy level at 
baseline. p values and 95% CIs for the model coefficients 
were obtained by bootstrapping. To ensure a familywise 
error rate at 5%, p values were adjusted using the false 
discovery rate method.12
If an individual responded “don’t know” to an item in 
the primary outcome measure, then they were excluded 
from the main analysis. For a sensitivity analysis con-
cerning missing data, missing data measuring vaccine 
hesitancy at the item level were assumed to be missing 
at random and thus multiple imputation was used.13 
Predictive mean matching was used as the imputa-
tion algorithm, which is appropriate for numerical data. 
The conditional predictive distribution of the item-level 
responses required to be imputed were adjusted to account 
for the information from age, gender, and level of 
COVID-19 health risk, all of which were known to be 
significant predictors of vaccine hesitancy as described in 
OCEANS-II.1 Only complete cases were used for age, 
gender, and level of COVID-19 health risk. Multiple 
imputation was imputed 50 times at the item level, and 
the responses from each imputed dataset were summed to 
create total hesitancy scores. The regression model was 
estimated 50 times and the predictions were averaged on 
the basis of Rubin’s rules14 to calculate the estimated 
marginal means.
Mediation analyses were carried out using structural 
equation modelling. The factor scores of the Oxford 
COVID-19 Vaccine Hesitancy Scale were the response 
variable with randomised group as the exposure and a 
higher-order latent variable (beliefs) derived from the 
four subscales of the Oxford Vaccine Confidence and 
Complacency Scale as the mediator variable. Age, gender, 
ethnicity, income, region, and level of COVID-19 health 
risk were included in the model as controls. We employed 
the Monte Carlo method for a formal inferential test of 
the effects in the mediation model.15
A statistical analysis plan was finalised before the 
unblinding of data for analysis (appendix pp 2–9). There 
were no interim analyses. In a post-hoc analysis, we exclu-
ded participants who had been vaccinated from the out come 
analyses, to assess whether their inclusion biased the 
results. For all analyses, participants were analysed in 
the groups they were allocated. Results were conducted 
in R (version 4.0.0) and then validated by a second statis-
tician (L-MY) in Stata SE (version 16.1). This trial was 
prospectively registered with ISRCTN, ISRCTN37254291.
Role of the funding source
Funding was provided by the National Institute for Health 
Research (NIHR) Oxford Biomedical Research Centre 
and the NIHR Oxford Health Biomedical Research 










If the vaccine was available at my GP surgery I would:
1. Get it as soon as 
possible
11 012 (73·3%) 0 2548 (49·8%)
2. Get it when I have 
time
1451 (9·7%) 0 1192 (23·3%)
3. Delay getting it 672 (4·5%) 976 (25·4%) 425 (8·3%)
4. Avoid getting it for 
as long as possible
771 (5·1%) 1164 (30·3%) 348 (6·8%)
5. Never get it 632 (4·2%) 893 (23·2%) 342 (6·7%)
6. Don’t know 476 (3·2%) 808 (21·0%) 259 (5·1%)
Stratification
Willing 12 463 (83·0%) 0 3740 (73·1%)
Doubtful 1148 (7·6%) 1784 (46·4%) 684 (13·4%)
Strongly hesitant 1403 (9·3%) 2057 (53·6%) 690 (13·5%)
The representative cohort was recruited from Jan 19 to Feb 5, 2021, with 
recruitment extended to Feb 18 for the additional vaccine-hesitant group. 
Participants in all cohorts are stratified according to their answers to the question 
displayed. GP=general practitioner.
Table 2: Vaccine hesitancy levels in the OCEANS-III and OCEANS-II 
cohorts
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Centre. The two funders had no role in study design, data 
collec tion, data analysis, data interpretation, or writing of 
the report.
Results
From Jan 19 to Feb 5, 2021, 15 014 adults were recruited as 
planned (figure). Vaccine hesitancy was notably lower than 
found in the OCEANS-II survey conducted in October, 2020 
(table 2). The largest reduction was in rates of those who 
were doubtful, although there had also clearly been a fall 
in the numbers of those who were strongly hesitant. 
Therefore, without a break and before analysis of the 
outcome results, we continued recruitment of vaccine-
hesitant individuals (ie, doubtful or strongly hesitant). 
Recruitment ended on Feb 18, 2021, which provided an 
additional 3841 participants. A summary of the socio-
demographic characteristics of the participants is given in 
table 3, with a breakdown by randomisation conditions 
provided in the appendix (pp 11–13). The three stratifica tion 
hesitancy groups differed significantly, as would be 
expected, in beliefs about the collective benefit, personal 
risk and efficacy, speed of development concerns, and side-
effect concerns. With increasing hesitancy level (willing to 
doubtful to strongly hesitant) there are increas ingly 
negative views on all subscales of the Oxford Vaccine 
Confidence and Complacency Scale (appendix p 53). 
1795 participants from the representative sample reported 
being vaccinated for COVID-19 and their hesitancy scores 
were significantly lower than the rest of the sample 
(p<0·00001). All 18 855 participants completed the primary 
outcome and 2400 participants who did not complete all 
items of the Oxford COVID-19 Vaccine Hesitancy Scale 
were excluded, meaning 16 455 were included in the 
primary analysis (figure).
We present the primary outcome results by stratification 
groups, since there was no indication of any main effect of 
condition (all adjusted p values >0·8; appendix pp 15–16) 
but there was moderation by vaccine hesitancy level 
(appendix p 19). The vaccine hesitancy estimated scores in 
each randomisation condition for each level of vaccine 
hesitancy are presented in table 4. Significant differences 
in vaccine hesitancy by information condition were only 
present for the strongly hesitant group, for whom con -
dition 5 (personal benefits), condition 7 (directly addres-
sing concerns about vaccine safety related to speed of 
development), and condition 10 (full combination) reduced 
vaccine hesitancy compared with the control condition 
(table 5). Condition 5 (personal benefits) led to the greatest 
reduction in hesitancy. There was no evi dence that the 
differences by information condition were explained by 
changes in COVID-19 vaccine views (appendix pp 34–35).
In planned comparisons between conditions (other than 
control), we found that in the strongly hesitant group, 
personal benefit information was more effective than 
information on the collective benefit of not personally 
getting ill or the collective benefit of not transmitting the 
virus, and it was worse to combine personal and collective 
benefits than just to provide personal benefit information 
alone (table 6). These differences were not explained by 
changes in COVID-19 vaccine views (appendix pp 35–36). 
Addressing speed of development directly or indirectly 
did not differ in effect on vaccine hesitancy in any of 
the groups (table 6). There was no difference for any of the 
Data (n=18 855)









Female 10 512 (55·8%)
Male 8155 (43·3%)
Non-binary 86 (0·5%)
Prefer not to say 102 (0·5%)
Ethnicity
White
English, Welsh, Scottish, Northern Irish, or British 14 053 (74·5%)
Irish 229 (1·2%)
Gypsy or Irish Traveller 83 (0·4%)
Any other White background 915 (4·9%)
Mixed or multiple ethnic groups
White and Black Caribbean 227 (1·2%)
White and Black African 105 (0·6%)
White and Asian 171 (0·9%)
Any other mixed or multiple ethnic background 209 (1·1%)





Any other Asian background 189 (1·0%)
Black, African, Caribbean, or Black British
African 641 (3·4%)
Caribbean 296 (1·6%)





Any other ethnic group 97 (0·5%)
Prefer not to say 231 (1·2%)
Marital status
Single 6684 (35·4%)




Prefer not to say 338 (1·8%)
(Table 3 continues in next column)
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groups in effectiveness of combining all the available 
information (condition 10) compared with combining 
only information about collective and personal benefits 
(table 6).
Forest plots of the effectiveness of each information 
con di tion, compared with the control, moderated by age, 
gender, income, COVID-19 severity risk, region, and 
ethnicity, are shown in the appendix (pp 24–32). In these 
subgroup analyses, a positive mean difference favours 
condition 1 (control), which can be interpreted as the 
hesitancy score being higher in the other information 
conditions. There are few indications of significant 
modera tion, although this information must be inter-
preted with caution as sample sizes are sometimes 
small. However, individuals of Black ethnicity tended to 
have an opposite reaction to some of the information 
conditions (ie, they had lower hesitancy scores for the 
control con dition) compared with other ethnicities, 
although this was only significant for condition 3 (collec-
tive benefit of not transmitting; mean diff er ence 1·25, 
95% CI 0·03 to 2·47; pinteraction=0·033). Condition 9 
(collective and personal benefit) was the only other 
condition to show significant differences by ethnicity, 
with Asian individuals showing the greatest reduction 
in hesitancy (–1·28, –2·26 to –0·31; pinteraction=0·038). 
Con di tion 5 (personal benefit) also had a greater impact 
Data (n=18 855)
(Continued from previous column)
Employment change due to COVID-19 pandemic
None 10 466 (55·5%)
None, but working from a different location 
(eg, working from home)
2589 (13·7%)
Working hours have reduced 2032 (10·8%)
Working hours have increased 609 (3·2%)
Furlough 1444 (7·7%)
Newly unemployed 1103 (5·8%)
Newly employed (full time) 352 (1·9%)
Newly employed (part time) 262 (1·4%)
Had COVID-19
Yes, a positive test 1273 (6·8%)
No, a negative test 5972 (31·7%)
Might have had it but not been tested 2173 (11·5%)
Not had it but not been tested 9125 (48·4%)
Other 312 (1·7%)
Risk for severe COVID-19 course
Low risk 11 121 (59·0%)
Moderate risk 5204 (27·6%)
Very high risk 1468 (7·8%)
Do not know 1062 (5·6%)
Vaccinated for COVID-19
No 16 604 (88·1%)
Yes, because in vulnerable group 886 (4·7%)
Yes, because in key-worker group 883 (4·7%)
Yes, for another reason 301 (1·6%)
Do not know 181 (1·0%)
Data are n (%) or mean (SD). 
Table 3: Baseline characteristics
Data (n=18 855)
(Continued from previous column)
Highest level of education
No qualifications 1252 (6·6%)
GCSEs grades A*–C (or equivalent) 5256 (27·9%)
AS levels (or equivalent) 795 (4·2%)
A levels (or equivalent) 5118 (27·1%)
Certificate of higher education (eg, BA, BSc, 
or equivalent)
4810 (25·5%)
Postgraduate qualifications (eg, MA, MSc, PhD, DPhil) 1624 (8·6%)
Total household income
<£15 000 2973 (15·8%)
£15 000–19 999 1867 (9·9%)
£20 000–29 999 3325 (17·6%)
£30 000–39 999 2682 (14·2%)
£40 000–49 999 1934 (10·3%)
£50 000–59 999 1367 (7·3%)
£60 000–69 999 910 (4·8%)
£70 000–99 999 1191 (6·3%)
£100 000–149 999 610 (3·2%)
£150 000 and above 301 (1·6%)
Prefer not to say 1695 (9·0%)
Housing situation
Rented from council 3279 (17·4%)




North East 820 (4·3%)
North West 2023 (10·7%)
Yorkshire and the Humber 1488 (7·9%)
East Midlands 1385 (7·3%)
West Midlands 1796 (9·5%)
East 1381 (7·3%)
London 2936 (15·6%)
South East 2605 (13·8%)
South West 1509 (8·0%)
Wales 892 (4·7%)
Scotland 1528 (8·1%)
Northern Ireland 492 (2·6%)
Pre-COVID-19 pandemic employment status
Unemployed 1693 (9·0%)
Employed full time 7730 (41·0%)





(Table 3 continues in next column)
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for men (–0·53, –0·91 to –0·14) than for women 
(pinteraction=0·019).
No participant contacted the lead author or ethics com-
mittee about any concerns about the study, which was 
taken as an indication of the absence of adverse events.
In a post-hoc analysis, the outcome analyses were 
repeated for only the 14 483 participants who had not been 
vaccinated). The same significant and non-significant 
findings were found, with three exceptions: in the strongly 
hesitant group, significant reductions in hesitancy 
were also observed with condition 3 (collective benefit 
of not transmitting the virus; mean difference –0·77, 
–1·44 to –0·11, adjusted p=0·0373), condition 4 (both 
collective benefits; –0·98, –1·64 to –0·32, adjusted 
p=0·0088), and condition 8 (indirectly addressing con-
cerns about vaccine safety related to speed of dev elop-








Condition 1 (control) 268 28·53 (28·05–29·01) 0·24
Condition 2 (collective 
benefit)
269 28·01 (27·54–28·49) 0·24
Condition 3 (collective 
benefit)
271 28·06 (27·58–28·53) 0·24
Condition 4 (collective 
benefit)
279 27·85 (27·38–28·32) 0·24
Condition 5 (personal 
benefit)
270 27·04 (26·57–27·51) 0·24
Condition 6 (seriousness) 263 28·29 (27·81–28·76) 0·25
Condition 7 (safety, direct) 261 27·62 (27·14–28·11) 0·25
Condition 8 (safety, indirect) 257 27·79 (27·30–28·28) 0·25
Condition 9 (collective and 
personal benefit)
284 28·17 (27·70–28·63) 0·24
Condition 10 (full 
combination)
264 27·67 (27·19–28·15) 0·24
Doubtful
Condition 1 (control) 160 20·49 (19·87–21·10) 0·31
Condition 2 (collective 
benefit)
157 20·71 (20·09–21·33) 0·32
Condition 3 (collective 
benefit)
181 20·51 (19·93–21·09) 0·30
Condition 4 (collective 
benefit)
167 20·13 (19·53–20·73) 0·31
Condition 5 (personal 
benefit)
169 20·79 (20·19–21·39) 0·31
Condition 6 (seriousness) 170 20·08 (19·49–20·68) 0·30
Condition 7 (safety, direct) 170 20·60 (20·00–21·20) 0·30
Condition 8 (safety, 
indirect)
171 20·88 (20·29–21·48) 0·30
Condition 9 (collective and 
personal benefit)
163 19·87 (19·26–20·48) 0·31
Condition 10 (full 
combination)
143 20·80 (20·15–21·45) 0·33
Willing
Condition 1 (control) 1209 9·39 (9·17–9·62) 0·11
Condition 2 (collective 
benefit)
1215 9·39 (9·16–9·61) 0·11
Condition 3 (collective 
benefit)
1211 9·37 (9·14–9·59) 0·11
Condition 4 (collective 
benefit)
1199 9·21 (8·98–9·43) 0·12
Condition 5 (personal 
benefit)
1224 9·24 (9·02–9·47) 0·11
Condition 6 (seriousness) 1213 9·42 (9·20–9·64) 0·11
Condition 7 (safety, direct) 1214 9·37 (9·15–9·59) 0·11
Condition 8 (safety, indirect) 1216 9·30 (9·08–9·53) 0·11
Condition 9 (collective and 
personal benefit)
1201 9·46 (9·23–9·68) 0·12
Condition 10 (full 
combination)
1216 9·18 (8·95–9·40) 0·11
Information conditions are outlined in table 1. Scores can range between 7 
and 35, with higher scores indicating higher COVID-19 vaccine hesitancy.
Table 4: Estimated vaccine hesitancy marginal means in each 
information condition across the vaccine hesitancy groups
Estimated mean difference 




Condition 2 (collective benefit) –0·51 (–1·19 to 0·16) 0·34 0·2171
Condition 3 (collective benefit) –0·47 (–1·14 to 0·20) 0·34 0·2254
Condition 4 (collective benefit) –0·68 (–1·35 to –0·01) 0·34 0·0846
Condition 5 (personal benefit) –1·49 (–2·16 to –0·82) 0·34 0·0015
Condition 6 (seriousness) –0·24 (–0·92 to 0·43) 0·35 0·5117
Condition 7 (safety, direct) –0·91 (–1·58 to –0·23) 0·35 0·0261
Condition 8 (safety, indirect) –0·74 (–1·42 to –0·06) 0·35 0·0703
Condition 9 (collective and personal benefit) –0·36 (–1·03 to 0·30) 0·34 0·3514
Condition 10 (full combination) –0·86 (–1·53 to –0·18) 0·34 0·0313
Doubtful
Condition 2 (collective benefit) 0·23 (–0·65 to 1·10) 0·45 0·7656
Condition 3 (collective benefit) 0·02 (–0·82 to 0·87) 0·43 0·9615
Condition 4 (collective benefit) –0·36 (–1·22 to 0·51) 0·44 0·7515
Condition 5 (personal benefit) 0·31 (–0·55 to 1·16) 0·44 0·7515
Condition 6 (seriousness) –0·41 (–1·26 to 0·45) 0·44 0·7515
Condition 7 (safety, direct) 0·11 (–0·74 to 0·97) 0·44 0·9178
Condition 8 (safety, indirect) 0·40 (–0·46 to 1·25) 0·44 0·7515
Condition 9 (collective and personal benefit) –0·62 (–1·48 to 0·25) 0·44 0·7515
Condition 10 (full combination) 0·32 (–0·58 to 1·21) 0·46 0·7515
Willing
Condition 2 (collective benefit) –0·01 (–0·32 to 0·31) 0·16 0·9741
Condition 3 (collective benefit) –0·02 (–0·34 to 0·29) 0·16 0·9497
Condition 4 (collective benefit) –0·19 (–0·50 to 0·13) 0·16 0·7443
Condition 5 (personal benefit) –0·15 (–0·46 to 0·17) 0·16 0·7924
Condition 6 (seriousness) 0·03 (–0·29 to 0·34) 0·16 0·9497
Condition 7 (safety, direct) –0·02 (–0·34 to 0·29) 0·16 0·9497
Condition 8 (safety, indirect) –0·09 (–0·41 to 0·23) 0·16 0·9477
Condition 9 (collective and personal benefit) 0·06 (–0·25 to 0·38) 0·16 0·9477
Condition 10 (full combination) –0·22 (–0·53 to 0·10) 0·16 0·7009
Estimated differences are between listed information conditions and the control group (ie, minus condition 1). 
Information conditions are outlined in table 1. Scores can range between 7 and 35, with higher scores indicating higher 
COVID-19 vaccine hesitancy.
Table 5: Mean difference between vaccine hesitancy marginal means for each randomised information 
conditions compared with control
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comparison with the control condition. Personal benefit 
information was still associated with the greatest lowering 
of hesitancy (–1·76, –2·42 to –1·09, adjusted p=0·0002), 
which was significantly greater than the collective benefit 
conditions (appendix pp 40–48).
The results from our sensitivity analyses using multiple 
imputation for missing data were comparable to those in 
the main analysis, showing that excluding the “don’t 
know” responses did not affect our findings (appendix 
pp 37–39).
Discussion
Since the start of the COVID-19 vaccination programme 
in the UK in December, 2020, hesitancy rates in the 
population appear to have substantially declined. The 
most notable shift has been towards people wanting to get 
the COVID-19 vaccination as soon as possible. Back in 
October, 2020, half the population wanted to get the 
vaccination as soon as possible; by the time of our study in 
February, 2021, that figure was closer to three quarters. 
This is greatly encouraging, although it is highly likely 
that there will be fluctuations depending on the content of 
news. A consequence for the study was the need to enrich 
the large representative participant cohort with individuals 
selected for COVID-19 vaccine hesitancy. This enrichment 
preserved the study power to test effectiveness of 
information conditions by initial vaccine hesitancy levels. 
As anticipated, this was important because reactions to 
the information conditions were affected by pre-existing 
hesitancy levels. The brief information provided, above 
that of a simple statement of efficacy and safety, did not 
alter hesitancy levels in those who were willing to be 
vaccinated or were doubtful (ie, would delay being 
vaccinated or did not know whether they would get 
the vac cine). However, there was an impact for people 
who were strongly hesitant about a COVID-19 vaccine 
(ie, would avoid getting it for as long as possible or never 
get it). Individuals who were strongly hesitant were less 
likely to see the collective benefit of vaccination and 
had greater safety concerns relating to the speed of 
development. The hesitancy levels of these individuals 
were reduced to a small degree by information that 
highlighted the personal benefits of vaccination or directly 
addressed speed of development concerns. It was clear 
that highlighting personal benefit was more effective than 
emphasising collective benefit for those who were strongly 
hesitant. It was also worse to combine personal and 
collective benefit for this group than to present personal 
benefits alone. Whereas a large majority of the population 
see the collective benefit and are willing to be vaccinated, 
simple presentation of the collective benefit rationale is 
less persuasive for the minority who have not previously 
accepted it. For this subgroup, it might be harder to shift 
perspective now to the collective benefits, but highlighting 
the personal perspective could have a greater attraction. In 
essence, belief in personal risk from vaccines might be 
best counterbalanced by personal-benefit messaging. 
Messag ing that reduces hesitancy for this group did not 
deter the rest of the population. As COVID-19 in all its 
variant forms is unlikely to vanish, it will probably be 
necessary to vaccinate the population on a regular and 
continuing basis. A high-stakes communi cations chal-
lenge on vac cina tion benefits will confront us for many 
years to come.
Overall, this study shows that brief, carefully crafted 
information can alter the willingness to be vaccinated 
for COVID-19 of those most strongly hesitant. The 
information could be used in online webpages or when 
contacting people to make vaccination appointments. 
However, this study showed no impact of messaging for 
people who were more mildly hesitant about vaccination 
or those already willing. Further work is needed to develop 
messaging that would be persuasive for the important 
group of people who are currently doubtful. Our find-
ings also indicate that gender and ethnicity, particularly 





Personal benefit (condition 5) vs collective benefit of not getting ill 
(condition 2)
Strongly hesitant –0·97 (–1·64 to –0·30) 0·34 0·0165
Doubtful 0·08 (–0·78 to 0·94) 0·44 0·9178
Willing –0·14 (–0·46 to 0·17) 0·16 0·7924
Personal benefit (condition 5) vs collective benefit of not transmitting 
(condition 3)
Strongly hesitant –1·01 (–1·68 to –0·35) 0·34 0·0150
Doubtful 0·28 (–0·55 to 1·12) 0·43 0·7515
Willing –0·12 (–0·44 to 0·19) 0·16 0·8211
Addressing speed of development directly (condition 7) vs indirectly 
(condition 8)
Strongly hesitant –0·17 (–0·52 to 0·85) 0·35 0·6355
Doubtful 0·28 (–0·56 to 1·13) 0·43 0·7515
Willing –0·07 (–0·38 to 0·25) 0·16 0·9477
Combining personal and collective benefits (condition 9) vs collective 
benefits alone (condition 4)
Strongly hesitant 0·32 (–0·34 to 0·97) 0·34 0·3980
Doubtful –0·26 (–1·12 to 0·60) 0·44 0·7515
Willing 0·25 (–0·07 to 0·57) 0·16 0·7009
Combining personal and collective benefits (condition 9) vs personal 
benefits alone (condition 5)
Strongly hesitant 1·12 (0·46 to 1·79) 0·34 0·0068
Doubtful –0·92 (–1·78 to –0·07) 0·44 0·3015
Willing 0·21 (–0·10 to 0·53) 0·16 0·7009
Combining collective and personal benefits, seriousness of the virus, 
and indirectly addressing safety concerns (condition 10) vs combining 
collective and personal benefits (condition 9)
Strongly hesitant –0·5 (–1·16 to 0·17) 0·34 0·2171
Doubtful 0·93 (0·04 to 1·82) 0·46 0·3015
Willing –0·28 (–0·60 to 0·04) 0·16 0·7009
Information conditions are outlined in table 1. Scores can range between 7 
and 35, with higher scores indicating higher COVID-19 vaccine hesitancy.
Table 6: Mean difference between vaccine hesitancy marginal means 
across randomised information conditions
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provision; this study was, however, underpowered to detect 
differences by particular ethnic groups. It is also reasonable 
to suppose that views of who is providing the information 
(in this instance, views of University of Oxford researchers) 
might affect the impact of infor mation, which was not 
tested in the study. Health-care services are typically the 
most trusted source for vaccination information.16 Our 
messaging text was written with the possibility in mind 
that it could be used in standard guidance from public 
health sources and could also be shared and communicated 
via different sources (eg, local community leaders). Our 
aim was to provide templates that could be reinforced 
through distribution and sharing. The study was only 
designed to detect which broad themes might reduce 
hesitancy, and could not determine whether smaller 
linguistic differences between the texts (eg, use of 
particular words or pronouns) could explain the different 
out comes. A future line of research could, for example, 
unpack different elements involved in the personal 
benefits thematic construct. The study certainly does not 
rule out that there could be more successful ways of 
presenting written information about any of the themes 
explored. The absence of detection of mediation by 
COVID-19 vaccine views leaves a further gap in under-
standing of the significant effects. Written information 
provision is only one aspect of encouraging vaccine 
acceptance, and, as this study shows, potentially has only a 
small effect. It is unknown how important this change 
might be. However, given the very large number of people 
who receive this form of communication, even small 
effects might be important. Future research could assess 
whether the impact of these messages increases, remains 
stable, or declines with repetition. The impact of different 
messages might also vary during the course of a vaccina-
tion programme. Written information could be even 
more powerful when combined with images, animations, 
videos, or reflective forms of engagement. This could 
be tested in future large-scale randomised controlled 
tests. Under certain conditions, written informa tion from 
institutional sources is also likely to be of benefit when 
reinforced by information provided by trusted peers and 
acquaintances via face-to-face conversations, social media, 
and private messaging apps.17
A limitation of this study is that expressed willingness to 
be vaccinated is unlikely to match exactly actual vaccination 
behaviour. A further limitation is that it is unknown 
whether the results will generalise more widely to the UK 
or to other countries. We used a non-probability online 
quota sampling method to recruit the majority of the 
participant group, which, while better than a convenience 
sample, will still have introduced bias to who was 
approached to take part. The recruitment of the additional 
vaccine-hesitant group will have skewed representativeness 
further. The success of the UK vaccination programme up 
to the point of the study, and generally high levels of 
vaccine acceptance in the UK, might mean the findings 
are of less relevance in other countries. In particular, the 
prevalence estimates of hesitancy must be treated with 
caution. The results of the randomised controlled tests of 
the information conditions can, however, be treated with 
much greater confidence.
OCEANS-III provides broad initial conclusions about 
COVID-19 vaccine information provision in the UK but 
there are numerous issues (eg, detailed dissection of 
messaging, impact in different groups, source of infor-
mation provision) that require detailed research attention. 
Developing such an evidence base about vaccination 
communication could be immensely important to the 
success of vaccination programmes.
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